Investors

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.

Approval of the issuance of new shares of common stock, as required by the NYSE American.
Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse stock split.
Approval of new directors to serve on its board.
BELGRADE, Mont., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the results of its Spe...

Conversion of $1.627M (plus interest) of convertible notes into common stock
Exchange of $70.238M (plus interest) of convertible notes into common stock
Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse stock split of common stock
Private placement of approximately $6.809M of common stock
Completion of transaction anticipated to allow Xtant to meet liquidity needs and reposition itself for long-term growth.
BELGRADE, Mont., Jan. 18, 2018 (G...